| Name | Title | Contact Details |
|---|
We are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.
Have a Heart`s core mission is to provide the medical, psychological and social benefits of one of the world`s oldest and safest medicines to those in need and to those looking for a safer alternative to alcohol and prescription and illicit drugs. Our goal is to do this in a manner that is innovative, legal and compliant and that provides the most wonderful experience for our guests, our employees and the community overall. We focus on improving the local aesthetic, reducing crime and providing employment to those seeking legitimate employment in the cannabis industry. We believe in providing our customers with the highest quality product in a comfortable, professional and safe environment. All of our locations are unique and have been designed for the comfort and entertainment of our customer. Our friendly and knowledgeable team is always willing to answer any questions, so you`ll find the correct product for your needs. At Have a Heart we have taken many steps to ensure that our customers feel the trust and passion for excellence they deserve.
Vitro Naturals is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LamdaGen Corp is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.